Literature DB >> 12605273

PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction.

H G Buchholz1, H Herzog, G J Förster, H Reber, O Nickel, F Rösch, P Bartenstein.   

Abstract

Quantitative imaging with the positron emitter (86)Y is the method of choice to determine the uptake and dosimetry of (90)Y-labelled radiopharmaceuticals. To examine the quantitative accuracy of positron emission tomography findings with (86)Y, this non-pure positron emitter was evaluated in a cylindrical phantom with rods of Teflon, water and air and measured with three different scanners: ECAT EXACT (2D/3D), ECAT HR+ (2D/3D) and PC4096+ (2D). After standard reconstruction, (86)Y radioactivity measured with the ECAT EXACT and related to the true radioactivity varied between 0.84 and 0.99 in 2D and between 0.93 and 1.20 in 3D from the first to the last acquisition (eight half-life times later). The water and Teflon rods exhibited considerable amounts of reconstructed radioactivity-21% in 2D and 67% in 3D for water and 65% and 147%, respectively, for Teflon-compared with the actual (86)Y radioactivity of the phantom. For the ECAT HR+ similar results were obtained in 3D, but there were even greater overestimations in 2D. Measurements with the PC4096+ showed rather small errors, with 10% for water and 20% for Teflon. To correct for the background of gamma-coincidences, sinograms were analysed and an experimental percentage of the background was subtracted from the sinograms. In order to minimise the errors in reconstructed radioactivity, the subtraction value had to be different for the individual scanners and modes. Our results demonstrate that (90)Y/(86)Y-based dosimetry for bone and red marrow must be regarded with caution if it is derived from regions of interest over the bone, the density of which is similar to that of Teflon. To obtain more reliable estimates, an appropriate background correction must be applied and tailored individually with respect to the scanner and acquisition mode.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605273     DOI: 10.1007/s00259-002-1112-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  10 in total

1.  Quantitative Imaging of Yttrium-86 with PET. The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions.

Authors: 
Journal:  Clin Positron Imaging       Date:  2000-05

2.  Quantitative imaging and correction for cascade gamma radiation of 76Br with 2D and 3D PET.

Authors:  Mark Lubberink; Harald Schneider; Mats Bergström; Hans Lundqvist
Journal:  Phys Med Biol       Date:  2002-10-07       Impact factor: 3.609

3.  Performance evaluation of the positron scanner ECAT EXACT.

Authors:  K Wienhard; L Eriksson; S Grootoonk; M Casey; U Pietrzyk; W D Heiss
Journal:  J Comput Assist Tomogr       Date:  1992 Sep-Oct       Impact factor: 1.826

4.  Performance characteristics of an eight-ring whole body PET scanner.

Authors:  E Rota Kops; H Herzog; A Schmid; S Holte; L E Feinendegen
Journal:  J Comput Assist Tomogr       Date:  1990 May-Jun       Impact factor: 1.826

5.  Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association.

Authors:  G Brix; J Zaers; L E Adam; M E Bellemann; H Ostertag; H Trojan; U Haberkorn; J Doll; F Oberdorfer; W J Lorenz
Journal:  J Nucl Med       Date:  1997-10       Impact factor: 10.057

6.  Correction for scattered radiation in a ring detector positron camera by integral transformation of the projections.

Authors:  M Bergström; L Eriksson; C Bohm; G Blomqvist; J Litton
Journal:  J Comput Assist Tomogr       Date:  1983-02       Impact factor: 1.826

7.  Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.

Authors:  G J Förster; M J Engelbach; J J Brockmann; H J Reber; H G Buchholz; H R Mäcke; F R Rösch; H R Herzog; P R Bartenstein
Journal:  Eur J Nucl Med       Date:  2001-10-20

8.  Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1- Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue.

Authors:  F Rösch; H Herzog; B Stolz; J Brockmann; M Köhle; H Mühlensiepen; P Marbach; H W Müller-Gärtner
Journal:  Eur J Nucl Med       Date:  1999-04

9.  Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography.

Authors:  F Rösch; H Herzog; C Plag; B Neumaier; U Braun; H W Müller-Gärtner; G Stöcklin
Journal:  Eur J Nucl Med       Date:  1996-08

10.  Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics.

Authors:  H Herzog; F Rösch; G Stöcklin; C Lueders; S M Qaim; L E Feinendegen
Journal:  J Nucl Med       Date:  1993-12       Impact factor: 10.057

  10 in total
  20 in total

1.  Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres.

Authors:  Renaud Lhommel; Larry van Elmbt; Pierre Goffette; Marc Van den Eynde; François Jamar; Stanislas Pauwels; Stephan Walrand
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-27       Impact factor: 9.236

2.  Assessment of the short-lived non-pure positron-emitting nuclide (120)I for PET imaging.

Authors:  H Herzog; S M Qaim; L Tellmann; S Spellerberg; D Kruecker; H H Coenen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-15       Impact factor: 9.236

3.  PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.

Authors:  Tapan K Nayak; Kayhan Garmestani; Kwamena E Baidoo; Diane E Milenic; Martin W Brechbiel
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

Review 4.  Radiolabeled bombesin derivatives for preclinical oncological imaging.

Authors:  Carolina de Aguiar Ferreira; Leonardo Lima Fuscaldi; Danyelle M Townsend; Domenico Rubello; André Luís Branco de Barros
Journal:  Biomed Pharmacother       Date:  2016-12-29       Impact factor: 6.529

5.  ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine.

Authors:  Ferid Haddad; Ludovic Ferrer; Arnaud Guertin; Thomas Carlier; Nathalie Michel; Jacques Barbet; Jean-François Chatal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

Review 6.  Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

Authors:  Stephan Walrand; Glenn D Flux; Mark W Konijnenberg; Roelf Valkema; Eric P Krenning; Renaud Lhommel; Stanislas Pauwels; Francois Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-11       Impact factor: 9.236

7.  Is bone marrow uptake of ⁸⁶Y-DOTATOC routinely observed?

Authors:  Stephan Walrand; Stanislas Pauwels; François Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

Review 8.  Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.

Authors:  Egesta Lopci; Arturo Chiti; Maria Rita Castellani; Giovanna Pepe; Lidija Antunovic; Stefano Fanti; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 9.  Quantitative imaging of 124I and 86Y with PET.

Authors:  Mark Lubberink; Hans Herzog
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

10.  Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.

Authors:  Andreas Helisch; Gregor J Förster; Helmut Reber; Hans-Georg Buchholz; Rudolf Arnold; Burkhard Göke; Matthias M Weber; Bertram Wiedenmann; Stanislas Pauwels; Ulrike Haus; Hakim Bouterfa; Peter Bartenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-03       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.